news
The immune system’s power over antibiotics for infections
The natural process of removing damaged cell parts could present an alternative to antibiotics, especially where bacteria have become resistant to existing drugs.
List view / Grid view
Cancer
news
What is the key source of T cell exhaustion?
US discovery opens the way to drugs that can prevent T cell therapies from losing their potency over time.
news
Enzyme opens door to new therapeutic targets for cellular stress
The activity of enzyme ATE1, as seen by US researchers, flags misfolded proteins for destruction and is enhanced by binding iron-sulphur clusters.
news
New self-powered drug delivery system
US researchers have invented a drug delivery technology that has implications for opioid epidemic, cancer treatment, rehabilitation care and more.
news
Therapeutic strategy using p53 induces cancer cell death
US researchers spotlight how p53, the most frequently mutated tumour suppressor gene, can be activated against cancer cells.
article
Latest in lab automation
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
news
What do cancer cells crave?
US researchers uncover the amino acid: arginine, that prompts genetic mutations in cancer cells.
article
Transforming the way cancer vaccines are designed and made
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
news
AI tools aid the discovery of super tight-binding antibodies
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
news
The role immunological memory plays in fighting disease
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
article
Developing state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
article
Allogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
news
New database maps proteins that could predict cancer
Swedish researchers unveiled a new cancer protein profile database compiled from artificial intelligence and machine learning.